Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Body composition has a major impact on survival, functionality and outcomes in people with chronic kidney disease (CKD). However, measurement of body composition in clinical practice is not routine or standardised. The Multimorbidity and Sarcopenia Study in CKD (MaSS-CKD) aims to study the changes in body composition in people with CKD using bioelectrical impedance analysis (BIA) over a year, and study its association with frailty, multimorbidity and performance status.
People with CKD stage 3, 4 and 5 were recruited together with an age and gender matched control group without kidney disease (eGFR >60ml/min/1.73m2) in a single centre. Exclusion criteria were: neuromuscular conditions, cardiac implantable electronic devices or pregnancy. Participants had body composition measured with the Inbody 770 device, frailty assessed with Clinical Frailty Scale (CFS), Karnofsky Performance Status Scale and multimorbidity quantified with Cambridge Multimorbidity Score (CMS) at baseline and at one year.
83 people were recruited to the study, and follow-up for the cohort is ongoing, expected to be completed in November 2025. Interim analysis was performed on 58 participants at one year, all with CKD (32 male, 26 female). After one year, 6 participants had died and one had become wheelchair bound and could not stand for the BIA.
Table 1 shows the demographics and characteristics of the participants at baseline and one year. Mean eGFR was 25.52 ml/min/1.73 m2 at baseline for the entire cohort. At one year, 5 participants had commenced dialysis (haemodialysis and peritoneal dialysis), and 1 participant received a kidney transplant. There was a drop in mean skeletal muscle mass of 0.74kg after one year, which was statistically significant (p=0.015). In addition, CFS score increased and Karnofsky Performance scores decreased after one year of follow-up (both p<0.001). The mean CMS increased in the cohort after one year (p=0.018).
The BIA findings suggest that body mass index (BMI) underestimated obesity both at baseline and at one year (Table 2). Based on BMI criteria 27.5% were obese at baseline and 29.8% at one year, but using percentage body fat criteria, obesity increased to 34.5% and 40.4% at baseline and one year respectively. Assessment for visceral obesity (visceral fat area >100cm2) revealed that 65.5% and 61.4% of participants met the criteria at baseline and one year, respectively. Mean whole body phase angle was low at baseline and one year (4.46° at baseline and 4.53° at one year).
In this interim analysis, we observed a significant loss of skeletal muscle mass over 1 year accompanied by negative change in performance status, frailty score and CMS. These findings may reflect underlying catabolic processes related to CKD, reduced physical activity which can contribute to sarcopenia and functional deterioration.
Percentage body fat and visceral fat area, measured by BIA, classified more participants with obesity than BMI-based classification. Visceral adiposity has been linked to increased metabolic syndrome, cardiovascular events and mortality risk. These measurements from BIA are potentially useful markers in clinical practice to identify those individuals at risk of poorer health outcomes, as targeted interventions with novel therapies could help improve prognosis.
